Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

Ebola virus under a microscope

The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola.

A planned sample of 26 participants – who must be assessed as healthy and aged 18 to 55 – will all receive one dose of the ChAdOx1 biEBOV vaccine at the University. Following vaccination, participants will be monitored through several visits over a six-month period, with results expected in the second quarter of 2022.

The vaccine is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca vaccine.

Professor Teresa Lambe OBE, Associate Professor at the Jenner Institute and Lead Scientific Investigator, University of Oxford, said: ‘The 2014-2016 Ebola virus disease outbreak in West Africa cost more than 11,000 lives and had a catastrophic effect on healthcare systems.

Read the full story on the University of Oxford website.

Similar stories

Misophonia: nearly one in five UK adults have the condition causing extreme reactions to certain sounds

Many of us have sounds that we find to be annoying. But for some people, certain sounds actually trigger extreme reactions.

Any type of hormonal contraceptive may increase risk of breast cancer

An analysis of data by researchers at the Nuffield Department of Population Health’s Cancer Epidemiology Unit has shown that use of progestogen-only hormonal contraceptives is associated with a 20-30% higher risk of breast cancer. The results are published in PLOS Medicine.

Viewing self-harm images on the internet and in social media usually causes harm, according to new review

Clinical researchers have reviewed the international research evidence regarding the impact of viewing images of self-harm on the internet and in social media.

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.